Published in Oncogene on October 17, 1996
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 6.87
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J (1998) 4.98
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol (2003) 2.45
A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc Natl Acad Sci U S A (2001) 1.88
MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J (2005) 1.85
Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J (2003) 1.85
MDMX regulation of p53 response to ribosomal stress. EMBO J (2006) 1.77
MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem (2009) 1.63
Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J (1999) 1.63
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J (2002) 1.45
Mdm2: the ups and downs. Mol Med (1999) 1.43
Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev (2010) 1.32
E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol Cell Biol (2002) 1.30
E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proc Natl Acad Sci U S A (2009) 1.28
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia (2009) 1.07
MTA1 coregulator regulates p53 stability and function. J Biol Chem (2009) 1.04
Gene profiling of MTA1 identifies novel gene targets and functions. PLoS One (2011) 0.88
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death Differ (2012) 0.88
Bidirectional autoregulatory mechanism of metastasis-associated protein 1-alternative reading frame pathway in oncogenesis. Proc Natl Acad Sci U S A (2011) 0.84
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. Int J Mol Sci (2016) 0.75
Mdm2 is required for survival and growth of p53-deficient cancer cells. Cancer Res (2017) 0.75
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ (2006) 2.95
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol (1994) 2.68
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ (2010) 2.43
Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A (1998) 2.11
p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun (2005) 2.03
A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell (2001) 1.88
Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev (1997) 1.88
The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol (2007) 1.83
NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem (1994) 1.73
High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A (2000) 1.73
Analysis of p53 mutants for transcriptional activity. Mol Cell Biol (1991) 1.73
Tissue-specific expression of the mouse alpha 2(I) collagen promoter. Studies in transgenic mice and in tissue culture cells. J Biol Chem (1992) 1.69
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene (2001) 1.66
A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene (2007) 1.55
Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst (1998) 1.46
Isolation and characterization of genomic DNA coding for alpha 2 type I collagen. Nucleic Acids Res (1980) 1.43
Reduced amounts of cartilage collagen fibrils and growth plate anomalies in transgenic mice harboring a glycine-to-cysteine mutation in the mouse type II procollagen alpha 1-chain gene. Proc Natl Acad Sci U S A (1991) 1.37
Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol (1999) 1.32
Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem (1996) 1.31
SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene (1993) 1.31
The loss of mdm2 induces p53-mediated apoptosis. Oncogene (2000) 1.31
p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene (2009) 1.29
Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J Virol (1987) 1.24
Crippling p53 activities via knock-in mutations in mouse models. Oncogene (2007) 1.19
The cenpB gene is not essential in mice. Chromosoma (1998) 1.17
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ (2008) 1.17
p53 sends nucleotides to repair DNA. Nature (2000) 1.16
A distinct class of vertebrate collagen genes encodes chicken type IX collagen polypeptides. Proc Natl Acad Sci U S A (1985) 1.15
Structure of the glycosaminoglycan domain in the type IX collagen-proteoglycan. Proc Natl Acad Sci U S A (1987) 1.11
The tumor suppressor p53 regulates its own transcription. Mol Cell Biol (1993) 1.08
Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene (2000) 1.07
MDM2 function. Biochim Biophys Acta (1998) 1.06
Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res (1998) 1.05
Construction and characterization of cDNA encoding the alpha 2 chain of chicken type IX collagen. Biochemistry (1985) 1.03
Fibrous hamartoma of infancy. J Am Acad Dermatol (1999) 1.02
Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene (2007) 1.02
Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene (2010) 0.99
Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene (1997) 0.97
The mutant p53 mouse as a pre-clinical model. Oncogene (2013) 0.97
Renal hydatid cysts: communicating with collecting system. AJR Am J Roentgenol (1980) 0.96
The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochem Biophys Res Commun (1999) 0.96
Isolation of the Aspergillus nidulans sudD gene and its human homologue. Gene (1998) 0.92
Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res (1997) 0.91
Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet (1998) 0.91
The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today (1997) 0.90
The organization and expression of the mdm2 gene. Genomics (1996) 0.90
A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene (2010) 0.90
Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest (1995) 0.89
An intron binding protein is required for transformation ability of p53. Nucleic Acids Res (1991) 0.88
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death Differ (2012) 0.88
p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death Differ (2002) 0.87
Transcriptional mechanisms controlling types I and III collagen genes. Ann N Y Acad Sci (1990) 0.87
Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ (2011) 0.87
Short-chain collagen genes and their expression in cartilage. Ann N Y Acad Sci (1985) 0.87
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg (2001) 0.86
The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene (1997) 0.86
Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. Mol Pharmacol (2001) 0.85
Serotonin 5-HT1C receptors are expressed at high density on choroid plexus tumors from transgenic mice. Brain Res (1986) 0.84
cDNA library screening using the SOS recruitment system. Biotechniques (2001) 0.83
Structural and functional analysis of p53: the acidic activation domain has transforming capability. Cell Growth Differ (1994) 0.83
Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis. Cell Death Differ (2013) 0.83
Cyclin E restores p53 activity in contact-inhibited cells. Mol Cell Biol (1995) 0.83
Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ (1999) 0.83
[Popular notions regarding "dengue" and "rompehuesos", 2 models of the disease in Colombia]. Rev Panam Salud Publica (2001) 0.83
Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet (1997) 0.81
Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature (2015) 0.81
Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene (2001) 0.80
Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene (1996) 0.80
Content of toxic heavy metals (mercury, lead, and cadmium) in canned variegated scallops (Chlamys varia). J Food Prot (2007) 0.79
Hybrid plasmonic-photonic modes in diffractive arrays of nanoparticles coupled to light-emitting optical waveguides. Opt Express (2013) 0.79
p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis (2001) 0.79
TP53 mutation and haplotype analysis of two large African American families. Hum Mutat (1999) 0.78
Novel p53 germline mutation in a patient with Li-Fraumeni syndrome. Intern Med J (2003) 0.78
Mapping of tyrosine hydroxylase in the diencephalon of alpaca (Lama pacos) and co-distribution with somatostatin-28 (1-12). J Chem Neuroanat (2013) 0.77
Germ cell expression of an isolated human endogenous retroviral long terminal repeat of the HERV-K/HTDV family in transgenic mice. J Virol (1999) 0.77
A functionally inactive p53 Li-Fraumeni syndrome mutant. Oncogene (1993) 0.77
Developmental control of transcription of the CAT reporter gene by a truncated mouse alphafetoprotein gene regulatory region in transgenic mice. Mol Reprod Dev (1995) 0.76
[Granulomatous hepatitis caused by Strongyloides stercoralis. Report of a case with histological confirmation]. G E N (1986) 0.76
A survey of bovine, bubaline and swine sarcocystosis in the Philippines. Southeast Asian J Trop Med Public Health (1997) 0.75
Mapping and mutational analysis of the human TAF2G gene encoding a p53 cofactor. Genomics (1999) 0.75
[Practical difficulties in the Rh prevention]. Acta Obstet Ginecol Hisp Lusit (1971) 0.75
[Antithrombotic treatment in non-rheumatic atrial fibrillation. Do we follow the recommendations of clinical trials?]. An Med Interna (1999) 0.75
Inhibition of the mutant p53 gene in transformation assays. J Surg Res (1992) 0.75
Mapping of tyrosine hydroxylase in the alpaca (Lama pacos) brainstem and colocalization with CGRP. J Chem Neuroanat (2010) 0.75
Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Mol Carcinog (1995) 0.75
Excitation of confined modes on particle arrays. Opt Express (2013) 0.75
[Prevention and treatment of Rh. isoimmunization. Results]. Acta Obstet Ginecol Hisp Lusit (1971) 0.75
A convenient cloning vector containing the GAL4 DNA-binding domain. Gene (1992) 0.75